8-K: Passage Bio Implements 1-for-20 Reverse Stock Split to Regain Nasdaq Compliance

Passage Bio, a clinical-stage genetic medicines company, announced a 1-for-20 reverse stock split effective July 14, 2025, aimed at regaining compliance with Nasdaq's minimum bid price requirement.

Summary

• Passage Bio, Inc. filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation to implement a 1-for-20 reverse stock split of its common stock.
• The reverse stock split will become effective at 12:01 a.m. Eastern time on July 14, 2025.
• The primary purpose of the reverse stock split is to regain compliance with Nasdaq's minimum bid price requirement of $1.00 per share.
• Stockholders approved a proposal on May 28, 2025, authorizing the Board of Directors to implement a reverse stock split at a ratio not less than 1-for-5 and not greater than 1-for-50.
• The Board of Directors approved the specific 1-for-20 ratio on June 26, 2025.
• Immediately prior to the reverse stock split, there were approximately 62,405,898 shares of Common Stock outstanding; after the split, there will be approximately 3,120,295 shares outstanding.
• No fractional shares will be issued; stockholders who would otherwise be entitled to receive fractional shares will receive the number of shares of Common Stock rounded up to the nearest whole share.
• The reverse stock split will not affect stockholders' ownership percentage (except for fractional share rounding), alter the par value of the Common Stock, change the number of authorized shares, or modify any voting rights or other terms.
• Proportionate adjustments will be made to the per share exercise price and the number of shares issuable upon the exercise of all outstanding stock options, and the number of shares reserved for issuance pursuant to the company's equity incentive and inducement plans, and employee stock purchase plan.
• The Common Stock will begin trading on a split-adjusted basis under a new CUSIP number, 702712 209, on July 14, 2025.

Sentiment

Score: 3

Explanation: The reverse stock split is a necessary action to maintain Nasdaq listing, which is a positive for continued trading. However, the underlying reason for the split (low stock price) indicates significant challenges and negative market sentiment regarding the company's performance or prospects. It's a corrective measure for a negative situation, not a sign of strong performance.

Positives

• The reverse stock split is intended to regain compliance with Nasdaq's minimum bid price requirement, which is crucial for maintaining the company's listing on the Nasdaq Capital Market and ensuring continued liquidity for investors.
• Stockholders who would otherwise be entitled to receive fractional shares will have their shares rounded up to the nearest whole share, which is a benefit to those specific shareholders.

Negatives

• A reverse stock split is typically a measure taken by companies whose stock price has fallen significantly, indicating underlying challenges or poor market performance.
• While addressing a listing requirement, the reverse stock split does not inherently resolve the fundamental reasons for the low stock price or improve the company's operational performance.

Risks

• There is a risk of non-compliance with Nasdaq's minimum bid price requirement if the stock price does not sustain above $1.00 per share post-split, potentially leading to delisting.
• The reverse stock split does not guarantee a sustained increase in stock price or address underlying business challenges, and the stock price could decline again.

Future Outlook

The company anticipates that the reverse stock split will enable it to regain compliance with Nasdaq's minimum bid price requirement, thereby maintaining its listing on the Nasdaq Capital Market. However, the company cautions that actual results or developments may differ materially from projected outcomes, and forward-looking statements could be affected by general industry and market conditions and regulatory approvals.

Management Comments

• The Board of Directors has approved a reverse stock split of the company's outstanding shares of common stock at a ratio of 1-for-20.
• The reverse stock split is intended to regain compliance with Nasdaq's minimum bid price requirement of $1.00 per share.

Industry Context

Reverse stock splits are a common strategy for clinical-stage biotechnology or genetic medicines companies, particularly those without commercialized products, as they often face challenges in maintaining stock prices above exchange minimums due to long development cycles, high R&D costs, and binary clinical trial outcomes. This action by Passage Bio reflects a broader trend among smaller biotechs to manage listing compliance while pursuing drug development.

Comparison to Industry Standards

• Many clinical-stage biotechnology companies, particularly those focused on niche or complex areas like neurodegenerative genetic medicines, experience stock price volatility and may resort to reverse stock splits to maintain exchange listings.
• The 1-for-20 ratio is within the typical range for such splits, often chosen to provide a sufficient buffer above the minimum bid price.
• The rounding up of fractional shares is a common practice that benefits small shareholders and is consistent with industry standards for reverse stock splits.

Corporate Governance

Stakeholder Impact

• Shareholders: The number of shares held will decrease by a factor of 20, but their percentage ownership will remain largely unchanged (except for fractional share rounding up). The action aims to prevent delisting, which would negatively impact liquidity and investor confidence.
• Employees: Proportionate adjustments will be made to outstanding stock options and shares reserved for equity incentive and employee stock purchase plans, ensuring their equity holdings are adjusted fairly.

Next Steps

• Common Stock will begin trading on a split-adjusted basis on July 14, 2025.
• The company will continue to monitor its compliance with Nasdaq listing standards.

Key Dates

Recommendation

Keywords

Passage Bio, PASG, Reverse Stock Split, Nasdaq Compliance, Stock Split, Genetic Medicines, Neurodegenerative Diseases, Clinical Stage, Equity Adjustment, Share Consolidation, 8-K Filing